Publication date: 20/08/2019
Liege, Belgium – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health today announces that it has entered into two exclusive license and supply agreements with Dexcel Pharma for the commercialization in Israel of two major products in contraception: the combined oral pill Estelle® and the hormonal ring Myring™.
Under the terms of these agreements, Dexcel will distribute Estelle® and Myring™ in Israel. Mithra will receive a down payment and recurring revenues based on minimum annual quantities (MAQ). Moreover, Mithra will manufacture both products at its Contract Development and Manufacturing Organization facility in Belgium. Dexcel Pharma is Israel’s largest private pharmaceutical company, which develops, manufactures and markets value-added branded and generic pharmaceuticals. With a diverse product portfolio that spans more than 85 branded and generic products in over 175 dosage forms, the products of Dexcel Pharma are sold in the US, the UK and Germany, via subsidiaries and through a trusted network of partners in more than 30 countries worldwide.
The agreement with Dexcel Pharma follows a number of licensing deals for Estelle® with key commercial partners in leading markets. In 2018, Mithra signed an exclusive long-term license and supply agreement with Gedeon Richter for the commercialization of Estelle® in Europe and Russia, as well as further agreements in Japan/ASEAN, Brazil, Canada, South Africa, South Korea and Middle East.
To date, Mithra has licensed Myring™ to industry leaders in ten international markets, including the United States, Austria, Czech Republic, Russia, Denmark, Chile, Australia/New Zealand, the MENA territories, South America and Israel. Further contracts are expected to follow in the next months, including in Europe, where Mithra will have 23 marketing authorizations granted.
François Fornieri, CEO Mithra Women’s Health, commented: “We are pleased to have finalized the agreement with the market leader Dexcel Pharma for the commercialization of our key contraceptive products in Israel. This new contract is clearly in line with our strategy to select the best-in-class partner to maximize the potential of our innovative products in core territories, as we are currently doing for future partnerships, particularly for the U.S.”
Mithra (Euronext: MITRA) is dedicated to providing innovation and choice in Women’s Health, with a particular focus on contraception and menopause. Mithra’s goal is to develop new and improved products that meet women’s needs for better safety and convenience. Its three lead development candidates – a fifth generation oral contraceptive Estelle®, the first complete oral treatment for perimenopause PeriNesta™ and next-generation hormone therapy Donesta® - are built on Mithra’s unique native estrogen platform, E4 (Estetrol). Mithra also develops and manufactures complex therapeutics and offers partners a complete spectrum of research, development and specialist manufacturing at its CDMO. Mithra was founded in 1999 as a spin-off from the University of Liège by François Fornieri and Prof. Dr. Jean-Michel Foidart. Mithra is headquartered in Liège, Belgium.
Further information can be found at www.mithra.com
The contents of this announcement include statements that are, or may be deemed to be, "forwardlooking statements". These forward-looking statements can be identified by the use of forwardlooking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.